ROSE AHF Ejection Fraction Differential Response
decongestion when compared with standard diuretic therapy alone. 4 Previous small studies that investigated the renal protective effects of low-dose dopamine included only subjects with HFrEF 5, 6 or did not examine the interaction between treatment allocation and EF. 7, 8 The ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) of nesiritide in AHF revealed no differential effect of nesiritide on symptom relief or outcomes in AHF patients with HFrEF or HFpEF but tested standard-dose nesiritide and did not examine the interaction between treatment effect and EF on decongestion and renal preservation. 1, 9 The objective of this post hoc analysis of the ROSE AHF study was to determine whether there are differential responses to low-dose dopamine or low-dose nesiritide in AHF patients with HFpEF versus HFrEF.
Methods

Study Overview
The ROSE AHF study design and results have been previously described. 4, 10 ROSE AHF was a double-blind, placebo-controlled, randomized clinical trial designed by and performed within the National Heart, Lung, and Blood Institute sponsored Heart Failure Research Network. The study was approved by each participating center's institutional review board, and all participants provided written informed consent.
Study Design
Patients (n=360) hospitalized with AHF and renal dysfunction were enrolled within 24 hours of hospital admission. Heart failure (HF) was defined by at least 1 HF symptom plus at least 1 HF sign. Renal dysfunction was defined as a glomerular filtration rate of 15 to 60 mL/min per 1.73 m 2 estimated by the Modification of Diet in Renal Disease equation. 11, 12 Patients were initially randomized in an open, 1:1 manner to the dopamine, or nesiritide strategy. Within each strategy, patients were randomized in a double-blind, 2:1 manner to the active therapy versus placebo group. The dopamine subjects received a 2 µg/kg per minute infusion for 72 hours. The nesiritide subjects received a 0.005 µg/kg per minute infusion for 72 hours with no loading dose of nesiritide. The placebo subjects were pooled across the 2 strategies and compared with the active therapy groups. All patients received openlabel intravenous loop diuretic therapy with a recommended initial dose of 2.5× the patient's outpatient oral loop diuretic, a 2000-mg sodium diet and a 2000-mL fluid restriction. Double randomization was performed to limit the number of patients requiring central lines for dopamine administration and to test the 2 independent hypotheses of dopamine and nesiritide. There was 1 placebo that differed by the route of administration to match the active treatment it was paired with, with blocks as small as possible given the trial design. The trial includes 26 participating centers across North America.
This subgroup analysis retrospectively analyzed the coprimary and secondary outcomes as defined in the ROSE AHF study by subdividing the dopamine, nesiritide, and pooled placebo groups based on EF ≤40% (HFrEF) or >40% (HFpEF). In the original ROSE AHF analysis, the prespecified subgroup analysis used 50% as the EF cutoff in defining HFrEF and HFpEF. 4, 10 However, in this analysis, we chose to use a cutoff of 40% so as to capture those with significantly impaired systolic function, recognizing that several large AHF studies have used a partition value of 40% when comparing AHF patients with HFrEF versus HFpEF. 3, 13 In addition, given the baseline characteristics and mean EF of the enrolled population, a cutoff of 40% allowed for more appropriate sample size in both EF groups. A sensitivity analysis was performed using 50% as the partition value for HFpEF and HFrEF, and comparison of results based on a 50% versus 40% cutoff can be found in the Data Supplement.
Outcome Measurements
The coprimary end points were decongestion, as measured by 72hour cumulative urine volume, and renal function preservation, as measured by change in cystatin-C from randomization to 72 hours.
Secondary outcomes included additional measures of decongestion (weight change, cumulative sodium excretion, change in N-terminal pro b-type natriuretic peptide (NT-proBNP), and incidence of treatment failure at 72 hours). Treatment failure was defined as the development of type 1 cardiorenal syndrome (CRS), worsening or persistent HF with the need for additional vasoactive agents, ultrafiltration, or mechanical respiratory support, significant hypotension or significant tachycardia. Secondary measures of changes in renal function included changes in creatinine and incidence of CRS (increase in creatinine of >0.3 mg/dL) at 72 hours. Symptom relief was assessed by the patient's global assessment of symptoms, measured with the use of a visual-analog scale and quantified as the area under the curve (AUC VAS) of serial assessments from baseline to 72 hours with a larger value indicating greater symptom relief. 14 Clinical outcomes including mortality (60 and 180 days) and mortality or HF rehospitalization by 60 days were assessed.
Statistical Methods
Unless otherwise noted, data are presented as median (25th-75th percentile) for continuous variables and as percent for categorical variables. Categorical baseline characteristics were compared with χ 2 tests or with Fisher exact tests in the case of small cell counts. Continuous variables were compared with Wilcoxon rank-sum tests. Continuous end points were modeled with linear regression models that included randomized treatment, EF group, and the treatment-by-EF group interaction. In the cases of weight, creatinine, cystatin-C, NT-proBNP, and VAS AUC change, models were also adjusted for the baseline measure. The c-index is the area under the receiver operating characteristic curve from logistic regression where models include the treatment effect, the binary EF category, and the treatment-by-EF category interaction. In the case of CRS, the model also adjusts for baseline creatinine value. For time to event end points, Harrell c-index is presented.
Multiple imputation was used to account for missing data in linear regression models. One hundred imputed datasets were created for each continuous end point where the following variables were included when creating the imputed datasets: age, sex, treatment, and values of the end point at baseline, 24, 48, and 72 hours. Linear regression was done for each data set, and results of the 100 models were combined. This method assumes that data are missing at random. Categorical end points at 72 hours were analyzed with logistic regression models that included randomized treatment, EF group, and the treatment-by-EF group interaction. The model for incidence of CRS was adjusted for baseline creatinine. Longer-term categorical end points (death and HF rehospitalization) were analyzed with Cox proportional hazards regression models. The summary statistics presented for 60-and 180-day end points are the number of events/ number of nonmissing follow-up time (Kaplan-Meier rate). P values for treatment effects within EF group are only shown if there is a significant interaction (P<0.05 for primary analysis and P<0.10 for sensitivity analysis). Data were analyzed with SAS version 9.4.
Results
Patient Population
There were 360 study participants enrolled in ROSE AHF between September 2010 and March 2013 at 26 sites in the United States and Canada. In this subgroup analysis, only 358 patients were included because baseline EF data were missing for 2 subjects. Of these, 222 (62%) had HFrEF and 136 (38%) had HFpEF. When compared with the HFrEF group, subjects in the HFpEF group were older, with a greater proportion being female and of white race ( Table 1 ). The subjects with HFpEF also had higher body mass index, systolic blood pressure, and prevalence of atrial fibrillation but fewer implantable cardiac devices or recent HF hospitalizations. The subjects with HFrEF were more likely to be on standard HF therapies than HFpEF subjects. Subjects in the HFpEF group had higher plasma cystatin-C with equivalent creatinine and estimated glomerular filtration rate and lower NT-proBNP compared with the HFrEF group.
In the HFrEF group, there were 76, 74, and 72 subjects in the placebo, dopamine, and nesiritide groups, respectively. In the HFpEF group, there were 43, 46, and 47 subjects in the placebo, dopamine, and nesiritide groups, respectively. The baseline characteristics were similar between the treatment groups within each EF group ( Table I in 
Low-Dose Dopamine Strategy
There was a differential effect of dopamine on decongestion between EF groups, including end points of 72-hour cumulative urine output ( Figure 1 ), sodium excretion, and treatment failure (interaction P<0.05 for all; Table 2 ). However, there was no differential effect of dopamine on 72-hour change in cystatin-C (interaction P=0.66; Figure 1 ) or NT-proBNP. There was also differential effect on clinical end points, including death at 60 or 180 days and death or HF rehospitalization at 60 days (interaction P<0.05 for all; Table 2 ).
In the HFrEF group, there was greater urine volume in the dopamine (8703 [7070-10 970] mL) versus placebo (7650 [5803-10 123] mL, P=0.029) group. In addition, in the HFrEF dopamine versus placebo group, there was greater weight reduction, but no significant difference in VAS AUC or incidence of CRS (Table 2 ). For clinical end points, in the HFrEF dopamine versus placebo group, there were fewer deaths at 60 or 180 days ( Table 2 ).
In contrast, in the HFpEF group, urine volume was lower in the dopamine (7300 [5450-8950] mL) versus placebo (8750 [7250-11 400] mL, P=0.010) group. In addition, in the HFpEF dopamine versus placebo group, there was less weight reduction, lower 72-hour sodium excretion, greater incidence of treatment failure, lower difference in VAS AUC, and higher incidence of CRS (Table 2 ). For clinical end points, in the HFpEF dopamine versus placebo group, there were significantly more deaths at 180 days, and higher incidence of death or HF rehospitalization at 60 days ( Table 2 ).
Low-Dose Nesiritide Strategy
There was a differential effect of nesiritide on decongestion between EF groups, including end points of 72-hour cumulative urine volume ( Figure 2 ), weight change, sodium excretion, and treatment failure (interaction P<0.05 for all; Table 3 ). However, there was no differential effect of nesiritide on 72-hour change in cystatin-C (interaction P=0.37; Figure 2) or NT-proBNP. In HFrEF, there was a nonsignificant trend for greater 72-hour cumulative urine volume in the nesiritide (9135 [6300-10 325] mL) versus placebo (7650 [5803-10 123] mL, P=0.074) group. In addition, in the HFrEF nesiritide versus placebo group, there was no difference in weight loss, 72-hour sodium excretion, or incidence of treatment failure.
In the HFpEF group, there was no difference in 72-hour cumulative urine volume in the nesiritide (8400 [5730-10 450] mL) versus placebo (8750 [7250-11 400] mL, P=0.22) group. In addition, in the HFpEF nesiritide versus placebo group, there was less weight reduction, lower 72-hour sodium excretion, and greater incidence of treatment failure (Table 3) .
There was no differential effect of nesiritide on clinical outcomes between the EF groups (Table 3) , and there was no differential effect of nesiritide on symptom relief (VAS AUC; interaction P=0.090; Table 3 ).
In summary, the results suggest that low-dose dopamine is associated with a beneficial effect on both surrogate and clinical outcomes in patients with HFrEF. In contrast, there is a signal for more adverse clinical outcomes with dopamine in patients with HFpEF. Furthermore, the effects of nesiritide on surrogate outcomes were better in HFrEF than in HFpEF, but there was no differential effect on clinical outcomes.
Sensitivity Analysis
Findings of this analysis were not meaningfully different when an EF of 50% was used as the partition value for HFrEF versus HFpEF (Tables II through V in the Data Supplement) . Patient characteristics between treatment groups in HFrEF and HFpEF did not differ ( Table II in the Data Supplement) . Similar to analysis using EF ≤40% or >40% to define HFrEF and HFpEF, there were significant (P<0.05) interactions between treatment allocation and EF group for both dopamine and nesiritide on the coprimary 72-hour cumulative urine volume end point but not on the coprimary change in cystatin-C end point ( Table III in the Data Supplement). Differential effects on secondary end points were also consistent with the primary subgroup analysis findings (Tables IV and V in the Data Supplement).
Analysis of patients with hypotension versus no hypotension on admission about interaction with intermediate variables and clinical outcomes demonstrated no clear pattern or evidence of differential effect by blood pressure. Through analysis of 3-way interaction of EF-by-treatment-by-hypotension, we do not see any evidence that the EF-by-treatment interaction is confounded or influenced by systolic blood pressure.
Discussion
The ROSE AHF trial did not find any significant enhancement in decongestion, renal function, or longer-term outcomes with low-dose dopamine or low-dose nesiritide when compared with placebo. 4 In this post hoc analysis, there were differential responses to both the agents on end points reflective of decongestion according to EF where dopamine enhanced decongestion in HFrEF but had an adverse effect on decongestion in HFpEF. Despite differential effects on decongestion, there was no interaction between treatment allocation and EF on changes in renal function. There was also evidence of a differential effect of dopamine (but not nesiritide) on survival at 60 and 180 days where relative to placebo, dopamine therapy was associated with improved outcomes in HFrEF but adverse outcomes in HFpEF. Although there were similar trends for differential effects on decongestion according to EF for nesiritide, the results with nesiritide were modest and unassociated with effects on outcomes in either HFrEF or HFpEF. Although differential response to chronic HF therapies in HFrEF and HFpEF is well established, these hypothesis-generating data suggest that investigation of AHF therapies should be powered to assess the potential for differential responses in AHF with preserved versus reduced EF.
Differential Response to Decongestive Therapies in HFrEF and HFpEF
Decongestion with diuretics or ultrafiltration is the cornerstone of AHF therapy. As recently reviewed, few studies have compared the efficacy of AHF treatments in HFrEF versus HFpEF. 15 The limited data available from AHF registries or cohort studies suggest that AHF patients with HFrEF or Data are median (25th-75th percentile) or n/n with data (%) unless noted. Continuous end points use multiple imputation data and categorical variables use nonmissing data. AUC VAS indicates area under the curve at 72 h for Global Well Being Visual Analog Score; CI, confidence interval; CRS, cardiorenal syndrome; EF, ejection fraction; n/a, not applicable; NT-proBNP, N-terminal pro b-type natriuretic peptide; HF, heart failure; and ReHsp, rehospitalization.
*Independent variables included in each model are EF category, randomized treatment, and the EF category-by-treatment interaction. In addition, models for change in weight, VAS, NT-proBNP, and creatinine also adjusted for the baseline value. Baseline creatinine was used for adjustment in the model for CRS >72 h. The c-index is shown in parentheses for the binary and time to event end points.
†P values for treatment effects within EF categories are only shown if there is a significant interaction.
HFpEF respond similarly to diuretics 3, 16 and ultrafiltration. 17 Thus, the differential effect of both low-dose dopamine and low-dose nesiritide on decongestion in diuretic-treated AHF patients with HFrEF or HFpEF is of interest.
There is a possibility that EF may be a surrogate for blood pressure as a variable in the differential effect findings. However, on 3-way analysis, there was no evidence of confounding blood pressure influence on the differential effect findings.
Differential Effects of Low-Dose Dopamine on Decongestion in HFpEF and HFrEF
Dopamine exerts its actions via 2 families of cell surface, G-protein-coupled receptors: D1-like receptors (D1 and D5) stimulate adenylyl cyclases, whereas D2-like receptors (D2, D3, and D4) inhibit adenylyl cyclases. The dopamine receptors are present in the kidney and renal vasculature where the endogenous dopaminergic system plays an important role in regulation of sodium excretion and blood pressure control. 18 Thus, dopamine infusion may augment natriuresis via effects on renal hemodynamics or tubular sodium reabsorption. With brief (3-5 minutes) infusion of dopamine at 2 µg/kg per minute in patients with HFrEF, renal blood flow increased and renal and systemic vascular resistance decreased. 19 Although the renal hemodynamic response to dopamine has not been characterized in human HFpEF, dopaminergic receptor function is impaired in animal models of hypertension and oxidative stress, both common in HFpEF. 20 Thus, in the patients with HFpEF, attenuated direct renal vascular and tubular effects may have contributed to the lack of enhanced diuresis and natriuresis as observed with dopamine in HFrEF.
Metra et al 21 demonstrated that in patients with HFrEF, dopamine at 2 µg/kg per minute (for 30 minutes) increased stroke volume and decreased systemic vascular resistance. Rajfer et al 22 compared the inotropic and vasodilatory effects of brief (10 minutes) infusion of incremental doses (2-10 µg/kg per minute) of dopamine and dobutamine and demonstrated that the load-independent inotropic effects of dopamine and dobutamine were similar at similar doses, whereas lower doses of dopamine also produced systemic vasodilatation and overall significant increases in cardiac index. These inotropic and vasodilatory systemic hemodynamic effects of low-dose dopamine may be more dramatic with sustained infusion as utilized in ROSE AHF and may contribute to the enhanced diuresis and natriuresis with dopamine in AHF patients with HFrEF. Indeed, in ROSE AHF, hypotension was less common in dopamine-treated patients suggestive of inotropic effects. 4 To our knowledge, no studies have characterized the inotropic or vasodilatory effects of dopamine in HFpEF. However, Schwartzenberg et al 23 compared the effect of vasodilatation with sodium nitroprusside in HFpEF and HFrEF. In HFrEF, nitroprusside resulted in minimal decreases in blood pressure and a marked increase in stroke volume. However, similar nitroprusside doses in patients with HFpEF resulted in greater blood pressure reduction and blunted increases in stroke volume when compared with HFrEF with a significant proportion (35%) of patients with HFpEF experiencing a reduction in stroke volume with acute vasodilator administration. These findings are consistent with the markedly steeper end-systolic pressure volume relationship in HFpEF versus HFrEF. Thus, in HFpEF, differential systemic hemodynamic response to the inotropic and vasodilatory effects of dopamine may have contributed to the adverse effect on decongestion observed in HFpEF.
Differential Effects of Low-Dose Nesiritide on Decongestion in HFpEF and HFrEF
The understanding of the effects of vasodilation between HFrEF and HFpEF subjects remain limited. 24 As noted above, Schwartzenberg et al 23 demonstrated that acute vasodilatation in patients with HFpEF resulted in greater blood pressure reduction and blunted increases (and frequently decreases) in stroke volume when compared with HFrEF. In the RELAX-AHF (Relaxin in AHF) trial of AHF patients with normal or increased blood pressure, the potent vasodilator serelaxin improved symptoms and reduced longer-term mortality with no differential effect on these end points in patients with EF ≤50% versus >50%. 25, 26 Overall, serelaxinand placebo-treated patients had similar weight loss at 5 days but with significantly lower diuretic doses in the serelaxin group. There was a greater diuretic sparing effect seen in the HFrEF group compared with the HFpEF group. These trends may suggest that the diuretic sparing effect of serelaxin was not as apparent in HFpEF. However, the relatively small numbers of patients with HFpEF in both studies and differences in population characteristics (different EF partition value and much higher blood pressure and lower cystatin-C levels in RELAX-AHF when compared with ROSE AHF) hinder comparisons. *Independent variables included in each model are EF category, randomized treatment, and the EF category-by-treatment interaction. In addition, models for change in weight, VAS, NT-proBNP, and creatinine also adjusted for the baseline value. Baseline creatinine was used for adjustment in the model for CRS over 72 h. The c-index is shown in parentheses for the binary and time to event end points.
had much lower 180-day postdischarge mortality (despite greater increases in creatinine) when compared with the group with less decongestion. 27 Thus, the differential effects of dopamine on outcomes may be related to the differential effects on decongestion. However, similar differences in outcomes with nesiritide in HFrEF and HFpEF were not observed, despite differences in decongestion, albeit less dramatic, with nesiritide in the 2 EF groups. Furthermore, the absolute number of events was low and these findings may be because of chance.
Definition of HFpEF
Studies have varied as to the EF value used to discriminate HFrEF from HFpEF in AHF. 3, 13, 25 Patients with an EF between 40% and 50% are problematic but generally are felt to have more of an HFpEF phenotype and guidelines do not endorse the use of standard HFrEF therapies in patients with an EF >40%. 24 Thus, for the purposes of this analysis, the partition value of 40% was used. This provided larger HFpEF sample size and more statistical power. Our sensitivity analysis indicates directionally and statistically concordant findings when an EF of 50% was used to define HFpEF.
Study Limitations
As noted above, the ROSE AHF study was not powered to detect differential treatment effects between the HFrEF and HFpEF groups, and the findings of this post hoc analysis could be because of chance alone. Our analyses did not transform continuous outcome variables. In a sensitivity analysis with log-transformed NT-proBNP as the outcome variable, the lack of a statistically significant interaction between the treatment and EF remained. Mechanisms accounting for observed interactions are not defined in this study. Future studies may consider the measurement of other important biomarkers because the degree of NT-proBNP change in this study does not seem to correlate with the dramatic clinical outcome differences. Given the dramatic clinical outcomes difference between the placebo and dopamine groups in HFrEF, there is a possibility that the results may be because of chance, and these hypothesis-generating findings should prompt further prospective studies given the physiological differences between HFrEF and HFpEF.
Conclusions
In this post hoc analysis of ROSE AHF, there were differential responses to low-dose dopamine and low-dose nesiritide based on EF in patients with AHF and renal dysfunction. Because differential response to chronic HF therapies in HFrEF and HFpEF is well established, these hypothesis-generating data suggest that investigation of AHF therapies should also assess the potential for differential responses in AHF with preserved versus reduced EF. The specific finding that adjunctive lowdose dopamine enhanced decongestion and was associated with improved posthospitalization outcomes among AHF patients with HFrEF group merits reexamination in a separate patient cohort. Furthermore, the findings of this study highlight the need for greater mechanistic understanding of the different phenotypes present in AHF and suggest that further prospective studies may benefit from greater characterization of AHF phenotypes in trial design when testing therapy.
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